A Resource for Healthcare and Social Services Professionals
Buprenorphine Extended-Release Implementation Guide
This comprehensive guide outlines key components for the successful implementation of buprenorphine extended-release injection for the treatment of opioid use disorder. It covers relevant definitions, identifies regulatory bodies, and highlights educational resources and tools to ensure regulatory compliance while providing high-quality patient care.
Download file
Boston Medical Center Injectable Buprenorphine Protocols
Please reference the 2021 Boston Medical Center OBAT Clinical Guidelines, pages 42-50.
These guidelines should be used to inform the administration of injectable buprenorphine at Boston Medical Center.
Visit webpage
Brixadi® Dosing Conversion Tables
Suggested Brixadi® corresponding dosage for patients transitioning from daily sublingual buprenorphine or monthly Sublocade® treatment to monthly or weekly Brixadi® treatment. Tables show the suggested corresponding Brixadi® dose based on current sublingual buprenorphine or Sublocade® dosage.
Download file
Consent for Treatment with Injectable Buprenorphine
Extended-Release Buprenorphine: An Instructional Guide
Extended-Release Injectable Buprenorphine Administration Checklist
Checklist for extended-release injectable buprenorphine administration. Please reference the 2021 "Addiction Nursing Competencies: A Comprehensive Toolkit for the Addictions Nurse" document, pages 62-63.
Visit webpage
Initiation of Brixadi® Extended-Release Injectable Buprenorphine for Opioid Use Disorder
Guidance for starting a patient on Brixadi® extended-release injectable buprenorphine for the treatment of opioid use disorder. This is not meant to replace clinical decision-making.
Download file
Initiation of Sublocade® Extended-Release Injectable Buprenorphine for Opioid Use Disorder
Guidance for starting a patient on Sublocade® extended-release injectable buprenorphine for the treatment of opioid use disorder. This is not meant to replace clinical decision-making.
Download file
Lidocaine Administration Prior to Extended-Release Buprenorphine Injection Protocols | Boston Medical Center
Boston Medical Center's Policy and Procedure Manual's Standing Order for Administration of Lidocaine prior to injection of extended-release injectable buprenorphine.
Grayken Center for Addiction TTA is a program of Boston Medical Center (BMC), a 514-bed academic medical center located in Boston's historic South End and the largest safety-net hospital in New England.
The content on this site and the content presented by Grayken Center for Addiction TTA is intended solely to inform and educate healthcare and social service professionals, and shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional. The hospital, the program, and the contributors are not acting as health care providers or professional consultants on behalf of any specific patient and disclaim establishing a provider-patient relationship with any specific patient.